The pharmacogenetics of antipsychotic-induced adverse events

Current Opinion in Psychiatry

Volumn 26, Issue 2, 2013, Pages 144-150

  Müller, Daniel J ^a   Chowdhury, Nabilah I ^a   Zai, Clement C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

antipsychotics; genetics; schizophrenia; tardive dyskinesia; weight gain

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CLOZAPINE; DOPAMINE RECEPTOR; GHRELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RELAXIN; RISPERIDONE; SEROTONIN 2C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AKATHISIA; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HORMONE ACTION; HUMAN; MENTAL PATIENT; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PARKINSONISM; PHARMACOGENETICS; PROMOTER REGION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; MOVEMENT DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; WEIGHT GAIN;

EID: 84873369266     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32835dc9da     Document Type: Review

References (53)

1. Lett TA, Wallace TJ, Chowdhury NI, et al. Pharmacogenetics of antipsychoticinduced weight gain: Review and clinical implications. Mol Psychiatry 2012; 17:242-266
2. Arranz MJ, Munro JC. Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia. Expert Rev Clin Pharmacol 2011; 4:389-405
3. Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep 2011; 13:156-165
4. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359:2086-2087 (Pubitemid 34680975)
5. Gregoor JG, Mulder H, Cohen D, et al. Combined HTR2C-LEP genotype as a determinant of obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2010; 30:702-705
6. Brandl EJ, Frydrychowicz C, Tiwari AK, et al. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38:134- 141
7. Chowdhury NI, Tiwari AK, Souza RP, et al. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics J 2012. doi: 10.1038/tpj.2011.66. [Epub ahead of print]
8. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012; 69:904-912
9. Zai GC, Zai CC, Chowdhury NI, et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychoticinduced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39:96-101
10. Yang Y, Li W, Zhao J, et al. Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients. Behav Brain Funct 2012; 8:11
11. Dubuquoy L, Dharancy S, Nutten S, et al. Role of peroxisome proliferatoractivated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002; 360:1410-1418 (Pubitemid 35341309)
12. Staeker J, Leucht S, Steimer W. Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: Lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. Mol Diagn Ther 2012; 16:93- 98
13. Souza RP, Tiwari AK, Chowdhury NI, et al. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J Psychiatr Res 2012; 46:462-468
14. Viollet B, Horman S, Leclerc J, et al. AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 2010; 45:276-295
15. Jassim G, Ferno J, Theisen FM, et al. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry 2011; 44:15-20
16. Callander GE, Bathgate RA. Relaxin family peptide systems and the central nervous system. Cell Mol Life Sci 2010; 67:2327-2341
17. Munro J, Skrobot O, Sanyoura M, et al. Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics. J Psychopharmacol 2012; 26:374-379
18. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C->T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA 2002; 288:2023-2031 (Pubitemid 35204693)
19. Ellingrod VL, Taylor SF, Dalack G, et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: The role of folate pharmacogenetics. J Clin Psychopharmacol 2012; 32:261-265
20. Devlin AM, Ngai YF, Ronsley R, Panagiotopoulos C. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Transl Psychiatry 2012; 2:e71
21. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 1993; 259:87-91 (Pubitemid 23036092)
22. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33:407- 418 (Pubitemid 29392689)
23. Kluge M, Schuld A, Schacht A, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009; 34:118-128
24. Schuld A, Kraus T, Haack M, et al. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 2000; 43 (2-3):164-166 (Pubitemid 30386885)
25. Huang HH, Wang YC, Wu CL, et al. TNF-alpha -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neurosci Lett 2011; 504:277- 280
26. Athanasiu L, Brown AA, Birkenaes AB, et al. Genome-wide association study identifies genetic loci associated with body mass index and high density lipoprotein-cholesterol levels during psychopharmacological treatment: A cross-sectional naturalistic study. Psychiatry Res 2012; 197:327- 336
27. Muller DJ, Schulze TG, Knapp M, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104:375-379 (Pubitemid 34280554)
28. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981; 138:1618-1619 (Pubitemid 12242831)
29. Youssef H, Lyster G, Youssef F. Familial psychosis and vulnerability to tardive dyskinesia. Int Clin Psychopharmacol 1989; 4:323-328
30. Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol 2011; 98:231-264
31. Zai CC, Hwang RW, De Luca V, et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10:639-651 (Pubitemid 47517514)
32. Zai CC, De Luca V, Hwang RW, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007; 12:794-795 (Pubitemid 47347796)
33. Koning JP, Vehof J, Burger H, et al. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) 2012; 219:727- 736
34. Tsai HT, North KE, West SL, Poole C. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:57-66
35. Utsunomiya K, Shinkai T, Sakata S, et al. Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: A reevaluation in East Asian populations. Neurosci Lett 2012; 507:52-56
36. Wang F, Fan H, Sun H, et al. Association between TNF-alpha promoter -308A/G polymorphism and tardive dyskinesian Chinese Han patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37:106- 110
37. Park SK, Nguyen MD, Fischer A, et al. Par-4 links dopamine signaling and depression. Cell 2005; 122:275-287 (Pubitemid 41032990)
38. Kim IS, Yoon HK, Kang SG, et al. No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients. Psychiatry Investig 2012; 9:191-194
39. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008; 321:848-851
40. Ivanova SA, Al Hadithy AF, Brazovskaya N, et al. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. Hum Psychopharmacol 2012; 27:334-337
41. Tsai HT, Caroff SN, Miller DD, et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:336-340
42. Ivanova SA, Loonen AJ, Pechlivanoglou P, et al. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia. Transl Psychiatry 2012; 2:e67
43. Bakker PR, Bakker E, Amin N, et al. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: A prospective study. PLoS One 2012; 7:e36561
44. Zhang XY, Zhang WF, Zhou DF, et al. Brain-derived neurotrophic factor levels and its val66met gene polymorphism predict tardive dyskinesia treatment response to ginkgo biloba. Biol Psychiatry 2012; 72:700- 706
45. Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gammaaminobutyric acid receptor signaling pathway are involved in neurolepticinduced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18:317-323 (Pubitemid 351367525)
46. Syu A, Ishiguro H, Inada T, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010; 35:1155-1164
47. Greenbaum L, Alkelai A, Zozulinsky P, et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2012; 6:513-520
48. Greenbaum L, Alkelai A, Rigbi A, et al. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 2010; 25:2809-2817
49. Aberg K, Adkins DE, Bukszar J, et al. Genome wide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67:279-282
50. Alkelai A, Greenbaum L, Rigbi A, et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009; 206:491-499
51. Greenbaum L, Smith RC, Lorberboym M, et al. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. Psychopharmacology (Berl) 2012; 220:519-528
52. Kasten M, Bruggemann N, Konig IR, et al. Risk for antipsychoticinduced extrapyramidal symptoms: Influence of family history and genetic susceptibility. Psychopharmacology (Berl) 2011; 214:729- 736
53. Schildcrout JS, Denny JC, Bowton E, et al. Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clin Pharmacol Ther 2012; 92:235-242.